The innovative pharmaceutical market continues to expand, with capital increasingly favoring the Hong Kong Stock Connect healthcare sector.

Release time：

2023-03-02

According to a report by the Foresight Industry Research Institute, China’s innovative pharmaceutical market has experienced rapid growth, driven by favorable policies, dynamic adjustments to the national medical insurance system, and increased R&D investment.

 　　According to a report by the Foresight Industry Research Institute, China’s innovative pharmaceutical market has expanded rapidly, driven by favorable policies, dynamic adjustments to the national medical insurance scheme, and increased R&D investment. Preliminary estimates from Frost & Sullivan indicate that the size of China’s innovative pharmaceutical market exceeded RMB 1.13 trillion in 2024. As the market continues to grow, the investment appeal of related indices has become increasingly evident. The CSI Stock Connect Healthcare Composite Index comprises 50 highly liquid, large-cap healthcare stocks eligible under the Stock Connect program. Recently, the Stock Connect Healthcare ETF (513200) has experienced net inflows for two consecutive weeks, totaling more than RMB 500 million. Its low expense ratio—just 0.15% per annum—has attracted a broad base of investors, making it an attractive option for gaining exposure to leading companies in the healthcare sector and reflecting sustained market optimism toward the pharmaceutical industry, particularly the innovative drug segment. 